Hims & Hers (HIMS) Jumps 48% Ahead of Earnings [Yahoo! Finance]
Novo Nordisk A/S (NVO)
Last novo nordisk a/s earnings: 2/5 01:31 am
Check Earnings Report
US:NYSE Investor Relations:
novonordisk.com/investors.html
Company Research
Source: Yahoo! Finance
Hims & Hers saw its share prices jump by 48.3 percent week-on-week as investors positioned portfolios ahead of the results of its earnings performance for the first quarter of the year, supported by optimism over its rekindled partnership with Novo Nordisk. In an updated report, Hims & Hers Health Inc. (NYSE:HIMS) said that it is scheduled to release the results of its earnings performance after market close on May 11, 2026. A conference call will be held to elaborate on the results. Praxis Precision Medicines, Inc. (PRAX) Gains Analyst Confidence With Ulixacaltamide Photo by Suzy Hazelwood on Pexels For the period, the company expects to grow its year-on-year revenues by 2.4 percent to 6.7 percent to a range of $600 million to $625 million, versus $586 million in the same period a year earlier. Adjusted EBITDA is projected at a range of $35 million to $55 million, or a decline of 40 percent to 61.6 percent from the $91.1 million in the same comparable period. Investors a
Show less
Read more
Impact Snapshot
Event Time:
NVO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NVO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NVO alerts
High impacting Novo Nordisk A/S news events
Weekly update
A roundup of the hottest topics
NVO
News
- Novo Nordisk: Etavopivat is the first in a new class of drugs to meet both co-primary endpoints in the phase 3 HIBISCUS trial, substantially reducing vaso-occlusive crisis events and improving haemoglobin response in sickle cell disease [Yahoo! Finance]Yahoo! Finance
- Novo Nordisk Announces Partnership with OpenAI [Yahoo! Finance]Yahoo! Finance
- Notable healthcare headlines for the week: J&J, Abbott and Organon in focus [Seeking Alpha]Seeking Alpha
- New Anthropic Board Member Signals Healthcare Push [Yahoo! Finance]Yahoo! Finance
- Novo GLP-1 drug shows less lean mass loss than rivals, study says [USA TODAY]USA TODAY
NVO
Earnings
- 2/3/26 - Beat
NVO
Sec Filings
- 4/20/26 - Form 6-K
- 4/13/26 - Form 6-K
- 4/7/26 - Form 6-K
- NVO's page on the SEC website